
GSK accelerates transformation with M&A and pipeline growth under new CEO, offering attractive investment potential.
GSK is speeding up its strategic transformation under new CEO Luke Miels by focusing on mergers and acquisitions, expanding its drug pipeline, and managing its HIV franchise proactively. The company plans to start over 20 Phase III clinical trials in...

